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Abstract 
Dicoumarol, a symmetrical biscoumarin can be considered as the “parent” of the widely used 
anticoagulant drug, warfarin.  The discovery of dicoumarol’s bioactive properties resulted from an 
investigation into a mysterious cattle disease in the 1940s.  It was then developed as a pharmaceutical, 
but was superseded in the 1950s by warfarin.  Both dicoumarol and warfarin antagonise the blood 
clotting process through inhibition of vitamin K epoxide reductase (VKOR).  This blocks the 
recycling of vitamin K and prevents the γ-carboxylation of glutamate residues in clotting factors.  
VKOR is an integral membrane protein and our understanding of the molecular mechanism of action 
of dicoumarol and warfarin is hampered by the lack of a three dimensional structure.  There is 
consequent controversy about the membrane topology of VKOR, the location of the binding site for 
coumarin inhibitors and the mechanism of inhibition by these compounds.  Dicoumarol (and warfarin) 
also inhibit a second enzyme, NAD(P)H quinone oxidoreductase 1 (NQO1).  This soluble, 
cytoplasmic enzyme may also play a minor role in the recycling of vitamin K.  However, its main 
cellular roles as an enzyme appear to be detoxification and the prevention of the build-up of reactive 
oxygen species.  NQO1 is well characterised biochemically and structurally.  Consequently, structure-
based drug design has identified NQO1 inhibitors which have potential for the development of anti-
cancer drugs.  Many of these compounds are structurally related to dicoumarol and some have 
reduced “off target” effects.  Therefore, it is possible that dicoumarol will become the “parent” of a 
second group of drugs. 
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Introduction:  Dicoumarol 
Dicoumarol (also dicumarol; 3,3'-methylenebis(4-hydroxy-2H-chromen-2-one); CAS # 66-76-2) was 
first synthesised in 1903 [1].  It was subsequently identified as a fungal metabolite of coumarin and 
the main cause of sweet clover disease, a haemorrhagic disease of cows and other livestock [2, 3].  
The compound is a symmetrical biscoumarin and has the potential to exist in three main tautomeric 
forms (Scheme 1) [4-6].  Further diversity is provided by rotation about the carbon atoms which link 
the two coumarin units and the possibility of ionisation of the hydroxyl groups [5].  A recent, 
theoretical, quantum chemical study predicted that dicoumarol will be predominantly in a negatively 
charged, syn-conformation in aqueous solution [7].  This is consistent with the experimentally 
determined pKa values (3.9 and 8.0) which predict that approximately 80% of the molecules will be in 
the singly ionised form at neutral pH [8].  Therefore, it is likely that this form of the compound is the 
one which predominates in most cells and, therefore, is the one that most commonly interacts with 
proteins. 
Following the discovery that dicoumarol can fatally inhibit clotting in farm animals, it was used 
pharmacologically as an anticoagulant [9].  It also had some use as a rat poison in agriculture [10].  
However, in both applications it was superseded by the related compound warfarin (Scheme 2) [11-
15].  Warfarin has the advantage of being more potent than dicoumarol and the sodium salt can be 
administered orally or by injection [16].  Dicoumarol continued to be used in the laboratory for a 
variety of applications, including as an uncoupler of the mitochondrial or bacterial membrane proton 
motive force [17].  In recent years, it has once again been receiving attention as a potential lead 
molecule in drug discovery – this time for anti-cancer agents, rather than for anticoagulants. 
 
Dicoumarol inhibits VKOR and antagonises blood clotting 
Despite their widespread use, the molecular mechanism of action of dicoumarol, warfarin and other 
coumarin-derived anticoalgulants remained elusive for around 40 years.  Initial observations 
demonstrated that the failure of blood clotting resulted from a defect in prothrombin and the effects of 
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these compounds could be antagonised by vitamin K [18-22].  Over time, it became apparent that 
these coumarin derivatives act by preventing the vitamin K-dependent γ-carboxylation of glutamate 
residues in the N-terminal regions of a range of clotting factors including prothrombin, factor VII, 
factor IX, factor X, protein C and protein S [23-26].  This post-translational modification enables 
these proteases to bind calcium and anchor themselves to the extracellular side of the cell membranes 
of platelets and other blood cells [27-32].  This membrane localisation is a critical event in the blood 
clotting cascade and, thus, a reduction in the extent of γ-carboxylation results in inhibition of clotting 
[33]. 
Vitamin K describes a set of related compounds which are a required part of the mammalian diet.  In 
plants, vitamin K1 (phylloquinone, phytomenadione, or phytonadione; CAS# 84-80-0; Scheme 3) 
dominates, whereas in animals vitamin K2 (the menaquinones) is more common.  In mammals, gut 
bacteria can convert vitamin K1 into menaquinone-4 (CAS# 863-61-6; Scheme 3) [34].  The vitamin 
is required for the γ-carboxylation of clotting factors.  It does not directly donate the carboxyl group, 
but participates in a cycle in which the vitamin is first reduced to the quinol form [35].  In a series of 
reactions catalysed by γ-glutamyl carboxylase (GGCX; EC 4.1.1.90), the reduced form of vitamin K 
is then oxidised by molecular oxygen.  The resulting peroxy derivative of the vitamin undergoes 
rearrangements to form oxy-epoxide vitamin K which can abstract a hydrogen atom from the target 
protein.  The target protein is left negatively charged and reacts with carbon dioxide becoming γ-
carboxylated in the process [36].  Vitamin K is left in the oxidised (keto) epoxide form (for structures 
of the various forms of vitamin K, see Scheme 4).  The oxidised form is regenerated by the action of 
vitamin K epoxide reductase (VKOR; EC 1.1.4.1) [37, 38].  Dicoumarol, warfarin and related 
compounds inhibit VKOR, thus preventing the recycling of vitamin K, “trapping” the molecule in the 
epoxide form, blocking the cycle and thus preventing the γ-carboxylation of clotting factors [33, 39-
41]. 
VKOR is a transmembrane protein with three or four membrane spanning regions in the human 
protein [38, 42-44].  Initially the enzyme was assumed to form part of a larger complex of proteins, 
hence its alternative name, vitamin K epoxide reductase complex subunit 1 (VKORC1) [38].  No 
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additional subunits have been definitively identified in humans.  However the equivalent bacterial 
protein has been shown to be fused to DsbA (a protein which catalyses disulphide bond formation) in 
some species [45].  In mycobacteria, the two proteins may be non-covalently associated and in some 
species of photosynthetic bacteria VKOR is fused to thioredoxin [46-48].  Despite its relatively small 
size (18.2 kDa), mammalian VKOR is capable of catalysing two reactions:  the conversion of vitamin 
K epoxide to vitamin K and the reduction of vitamin K to the hydroxy form [49].  The functionally 
active form of the enzyme is a multimer, most likely a dimer [50]. 
The catalytic mechanism of epoxide reduction by VKOR involves two cysteine residues (Cys-132 and 
Cys-135) in the membrane-embedded part of the protein which form a disulphide bond during the 
course of the reaction [44, 51-53].  The initial step most likely requires the protonation of the epoxide 
oxygen by one of the two cysteine residues followed by the formation of a covalent enzyme-substrate 
complex mediated by the second cysteine residue.  This carbon-sulphur bond is subsequently broken 
when a sulphur-sulphur bond between two cysteine residues in VKOR is formed [54].  These two 
cysteine residues must be re-reduced to regenerate active enzyme; it is assumed that this reduction is 
catalysed by a second protein, but the identity of this is not known.  Warfarin and other coumarins are 
reported to act as non-competitive inhibitors with respect to vitamin K epoxide [55-57].  True non-
competitive inhibitors (i.e. those which affect Vmax but not Km) are considered to be rare [58].  To 
achieve true non-competitive inhibition, the inhibitor must bind to a site away from the active site 
with equal affinity to the free enzyme and the enzyme substrate complex [58].  This would be difficult 
to verify experimentally, but it infers that vitamin K epoxide binding causes little overall change to 
the conformation of VKOR.  Interestingly, warfarin is also reported to act as a competitive inhibitor 
with respect to the reductant dithiothreitol (DTT) which is used experimentally as the reducing agent 
in the reaction.  Competitive inhibition requires binding at the same site [58].  This suggests that the 
vitamin K epoxide and reducing agent binding sites may be spatially separated in the enzyme which 
would require electrons to pass through the enzyme between the two binding sites.  It has been 
postulated that two surface exposed cysteine residues in the cytoplasmic domain may shuttle electrons 
to the active site in the vitamin K reduction reaction, raising the possibility that something similar 
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may occur in the reduction of the epoxide [59].  An alternative mechanism has been proposed in 
which warfarin acts as an irreversible inhibitor of VKOR, forming a covalent adduct with one of the 
active site cysteine residues [60, 61].  This is consistent with the concept that warfarin (and other 
coumarins) mimic the action of vitamin K in the reaction cycle and form covalent intermediates with 
the enzyme.  However, there is no direct evidence for a covalent VKOR-warfarin adduct. 
A more complete understanding of how warfarin (and other coumarins, including dicoumarol) 
interacts with VKOR has been hampered by the lack of a high resolution crystal structure of the 
enzyme.  A structure of the equivalent enzyme from the cyanobacterium Synechococcus sp. has been 
solved in complex with thioredoxin (PDB:  3KP9) [47].  The structure revealed four transmembrane 
helices and a quinone molecule bound in the transmembrane region (Figure 1a).  It also suggested an 
electron transfer pathway in which the thioredoxin subunit first reduces two surface cysteine residues 
which then transfer their electrons to the active site cysteines.  The quinone acts as the final electron 
acceptor in this model, which is consistent with the enzyme kinetics and non-competitive inhibition 
evidence described above for mammalian VKOR [47]. 
There is uncertainty about the membrane topology of mammalian VKOR.  Based on its similarity to 
the cyanobacterial enzyme, it has been suggested that it will have four transmembrane segments [47].  
Molecular models based using methods such as Phyre or SwissModel which search the Protein 
Databank for the most similar proteins and base the models on these will, inevitably, return structures 
with four transmembrane helices (Figure 1b).  However, other experimental and bioinformatics 
studies suggest that the mammalian enzymes differ and only have three transmembrane segments [42, 
43]. 
There is further uncertainty about the binding site for dicoumarol, warfarin and other coumain 
inhibitors.  Based on the structure of the cyanobacterial enzyme, it was suggested that warfarin binds 
at the same site at the quinone seen in the structure (and that vitamin K epoxide would also interact at 
this site) [47].  This is consistent with the locations of some of the mutations which alter the sequence 
of rat VKOR conferring resistance to warfarin and those which are associated with hereditary clotting 
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deficiencies in humans [55, 62-67].  Many of these variant forms of VKOR have lower catalytic 
activity than the wild-type and it is presumed that this loss of fitness is a “price worth paying” for 
resistance to rat poison [68].  The majority of these mutations affect residues which are predicted to 
be part of, or close to, the cleft which binds the quinone in the cyanobacterial enzyme (Figure 2).  
This suggests that the equivalent site in the mammalian enzyme is the binding site for warfarin and, 
possibly, vitamin K epoxide since the catalytic cysteine residues lie towards the base of this cleft.  
However, this would predict that warfarin (and other coumarins) should be not be non-competitive 
inhibitors with respect to vitamin K epoxide. 
The uncertainty about the membrane topology and coumarin binding site in VKOR makes molecular 
modelling studies particularly challenging.  Using a homology model based on the cyanobacterial 
structure, docking with AutoDock Vina as implemented in Chimera [69, 70], predicted that both 
dicoumarol and warfarin would bind at the base of the cleft with partially overlapping binding sites 
(Figure 3).  These models predict that the ligands bind close to some residues implicated in warfarin 
resistance, notably Ala-26, Trp-59, Glu-67, His-68, Gly-71, Leu-120 and Tyr-139 [55, 62-67, 71].  
However, given the uncertainties in the tertiary structure of the enzyme and the inherent risk of 
docking into a homology model, these predictions should be viewed with considerable caution.  
Notwithstanding these difficulties, models based on a membrane topology of four transmembrane 
helices each embedded in phospholipid to simulate the membrane have been used in computer-aided 
drug design [72].  The model was used to understand the interaction of a set of 4-hydroxycoumarins 
with polar substituents.  In general, predicted binding energies correlated well with physiological 
measurements such as the prothrombin time [72].  The most active compound (diethyl [1-(4-hydroxy-
2-oxo-2H-chromen-3-yl)ethylidene]propanedioate; Scheme 2) had similar pharmacological properties 
to warfarin and is predicted to form three hydrogen bonds to residues in the active site of VKOR [72].  
Based on this work, further compounds were synthesised with polar substituents at the same position.  
The most of active of this group of compounds was (3E)-3-{1-[(2-aminoethyl)amino]ethylidene}-4-
hydroxy-3,4-dihydro-2H-chromen-2-one (Scheme 2); this molecule caused reduced liver necrosis and 
oxidative stress compared to warfarin [73].  Additional computational studies suggested that the mode 
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of interaction of this group of compounds involves non-covalent bonding in which a proton from Cys-
135 partially transfers from the protein to the carbonyl oxygen on the ligand [72, 73]. 
 
Dicoumarol also inhibits NQO1 
Dicoumarol (and warfarin) also inhibit another enzyme implicated in vitamin K metabolism.  This 
enzyme, NAD(P)H quinone oxidoreductase 1 (NQO1, DT-diaphorase; EC 1.6.5.2) has very different 
structural and physical properties to VKOR.  NQO1 is a soluble, cytoplasmic, globular dimeric 
enzyme with two active sites [74-77].  Each of these active sites is composed of residues from both 
polypeptide chains [77].  The enzyme catalyses the NADH or NADPH-dependent reduction of a 
variety of organic compounds, including quinones [78-82].  Its cellular role is not wholly clear, but it 
seems likely that NQO1 participates in the detoxification of xenobiotic compounds and also in the 
cycling of quinones in the cell [75].  Since it catalyses the two electron reduction of quinones directly 
to the corresponding quinols, it avoids the production of potentially damaging semiquinones [83]. 
Although NQO1 has been shown to catalyse the reduction of menadione (a vitamin K derivative) in 
vitro, the role of the enzyme in vitamin K metabolism is not clear [83].  In addition to VKOR, there 
appear to be other enzymes which can catalyse the conversion of vitamin K to the reduced form.  
However, NQO1’s contribution to this process has been questioned:  NQO1 deficient mice were still 
able to generate reduced vitamin K, even in the presence of warfarin suggesting that an enzyme other 
than VKOR and NQO1 is also able to catalyse this process [84].  The interpretation of these types of 
experiments is undoubtedly complicated by the fact that warfarin and dicoumarol inhibit both VKOR 
and NQO1 (and, most likely, other cellular processes). 
NQO1 operates by a substituted enzyme (“ping-pong”) mechanism in which NAD(P)H reduces a 
tightly bound FAD cofactor and the resulting NAD(P)
+
 then leaves the active site.  This enables the 
second substrate (e.g. a quinone) to enter and be reduced by the FADH2 cofactor [85].  Dicoumarol is 
a competitive inhibitor of NQO1 with respect to NADH [86].  Interestingly, NQO1 displays negative 
cooperativity towards dicoumarol as an inhibitor, but not towards NAD(P)H as a substrate [86, 87].  A 
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recent computational study suggested that this cooperativity most likely arises from altered flexibility 
of “communication pathways” linking the two active sites [87].  This was confirmed by site-directed 
mutagenesis of a key glycine residue in one of these pathways:  alteration of this glycine to the more 
conformationally restricted serine dramatically reduced the enzyme’s cooperativity towards 
dicoumarol [87].  The physiological significance of this negative cooperativity is, as yet, unknown.  
However, it is interesting to note that similar effects have also been observed in the related human 
enzyme NRH-quinone oxidoreductase 2 (NQO2) and the budding yeast quinone oxidoreductase 
Lot6p [88, 89].  The crystal structure of NQO1 bound to dicoumarol shows that the ligand binds to 
both active sites, lying above the isoalloxazine ring of the FAD cofactors [90].  This molecular 
mechanism of inhibition is consistent with the observation of competitive inhibition since it is 
expected that NAD(P)H also binds above the FAD molecule in order to facilitate the transfer of 
electrons [77].  The inhibition of NQO1 by warfarin has received less attention [91, 92].  However, it 
seems likely that its mode of inhibition and site of interaction will be similar to dicoumarol. 
The inhibition of NQO1 has received increased attention recently.  The enzyme is highly expressed in 
several different cancer cell types [93].  One role of NQO1 in these cells appears to be to help defend 
them against oxidative damage [94, 95].  Therefore, inhibition of the enzyme may directly, or in 
combination with other therapies, result in the selective death of tumour cells.  Indeed, dicoumarol has 
been shown to inhibit the growth of pancreatic cancer cells [94].  While dicoumarol is unlikely to 
have great success as an anticancer agent owing to its anticoagulant properties, considerable efforts 
have been made to identify related structures which combine increased potency of inhibition of NQO1 
while reducing the other effects of the drug.  Paradoxically, mutations in the gene encoding NQO1 
which result in reduced enzymatic activity predispose people to cancer [96].  The best characterised 
cancer-associated variant is p.P187S (NQO1*2; rs1800566) and approximately a quarter of the human 
population have at least one allele which codes for this [97-99].  A rarer allele codes for p.R139W 
(NQO1*3; rs1131341) which is associated with childhood acute lymphoblastic leukaemia [100].  The 
fundamental biochemical cause of the loss of NQO1 activity in both variants is decreased stability of 
the protein and, in the case of p.P187S, consequent loss of the FAD cofactor [98, 101-103].  
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Therefore, there is also interest in discovering reagents which stabilise the cancer-associated variant 
forms of NQO1. 
To date, the majority of efforts to identify novel coumarin-like inhibitors of NQO1 have centred on 
computational studies backed up by in vitro testing.  The availability of several high resolution crystal 
structures of NQO1 makes such a strategy viable [77, 90, 104-106].  Of particular interest is the 
structure with dicoumarol bound (PDB:  2F1O; Figure 4) [90].  This provides a useful structure to 
compare modelled structures with since we would expect other coumarins to bind in a similar way to 
dicoumarol. 
In addition to its catalytic roles, NQO1 interacts with the apoptosis regulating protein p53.  This 
interaction stabilises p53 and promotes apoptosis.  Curcumin (Scheme 5) is an NQO1 inhibitor which 
reduces the growth of cancer cells in culture [107].  Curcumin antagonises this interaction, releasing 
p53 from the complex and promoting its degradation [107].  Dicoumarol has a similar effect on 
NQO1’s interaction with p53 [108-112].  The stability of ornithine decarboxylase and p73 are also 
regulated by binding to NQO1; in both cases dicoumarol antagonises the interaction [112, 113].  
Therefore, any attempts to develop inhibitors of NQO1 catalysis will need to take into account the 
protein’s second role as a stabiliser of a diverse range of cellular proteins. 
One of the first attempts to develop novel inhibitors of NQO1 with similar structures to dicoumarol 
involved the computational screening of the 700,000 compounds then available in the National 
Cancer Institute’s (USA) virtual library [114].  The screening method was validated by docking the 
known inhibitor, EO9 into the active site of NQO1 and comparing this with the crystal structure of the 
protein with the ligand bound [106].  Molecules identified in the initial computational screen were 
reduced in number by eliminating those which were too large (>500 Da) and those which were 
predicted to have unfavourable pharmacokinetic properties.  From this reduced list 21 compounds 
which were available for testing were assayed in vitro for their ability to inhibit NQO1.  All 21 
inhibited the enzyme’s ability to catalyse the reduction of menadione [114].  The compound with the 
highest experimentally determined IC50, NSC645827 (CAS# 128113-19-9; Scheme 5) shares some 
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structural features with coumarins, as do many of the other compounds identified in this process 
[114].  A further study mined the NCI database specifically for compounds with the coumarin 
scaffold.  The highest affinity binders were dicoumarol and its 4-hydroxy-substitued analogue, (3-
[(4,7-dihydroxy-2-oxochromen-3-yl)methyl]-4,7-dihydroxychromen-2-one) (NSC682612; CAS# 
63844-74-6; Scheme 5) [115].  This compound has a lower affinity for serum albumin compared to 
dicoumarol. Along with two others – 7-(4-hydroxy-2-oxochromen-3-yl)-7H-chromeno[3,2-
c]chromen-6-one (NSC686396) and NSC68639 (Scheme 5) – this compound causes a lower increase 
in superoxide generation and a lower oxidative respiratory burst compared to dicoumarol [115].  
These two effects are likely to arise from dicoumarol’s ability to uncouple the mitochondrial proton 
motive force and, from these data, it can be assumed that these three compounds are less effective in 
generating this “off-target” effect.  All three compounds inhibited the growth of pancreatic cancer 
cells in a dose-dependent manner [115].   
A series of 29 symmetrical and asymmetrical analogues of dicoumarol were synthesised and tested for 
their ability to inhibit NQO1 [105].  In general the asymmetric series had greater aqueous solubility 
compared to dicoumarol.  Three of the symmetrical analogues had higher affinity for NQO1 than 
dicoumarol (Scheme 5) [105].  One of the 29 inhibitors was co-crystallised with NQO1 and the 
resulting structure (PDB:  3JSX) compared to the docked model; the experimental and theoretical 
structures of the complex were in good agreement, further validating the structure-based drug design 
approach in this case [105].  These novel compounds inhibited NQO1 in colon, lung and pancreatic 
cancer cell lines and the degree of cellular inhibition broadly correlated with the in vitro affinity 
[116].  However, the “off target effects” of these compounds (superoxide generation, induction of 
apoptosis) were generally less than observed with dicoumarol.  The magnitude of these effects did not 
correlate with the in vitro affinity suggesting that they are true “off target” effects resulting from the 
compounds’ interactions with other biomolecules and systems within the cells [117]. 
 
Conclusions 
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Dicoumarol inhibits two different enzymes implicated in vitamin K metabolism – VKOR and NQO1.  
Given the very different nature of the two enzymes and their active sites, this appears to be a 
coincidence.  Attempts to understand the interaction of dicoumarol (and other coumarins) with VKOR 
have been hampered by the lack of structural information on the enzyme.  In contrast, the inhibition of 
NQO1 is very well understood through a number of biochemical, structural and computational 
studies.  This has enabled the development of novel inhibitors with more promising properties.  
Another interesting coincidence is that, while dicoumarol was the first well-established inhibitor of 
both VKOR and NQO1, it is structural derivatives of the compound which have greater 
pharmacological promise.  In the case of VKOR, warfarin has been phenomenally successful and is 
one of the world’s bestselling drugs [118].  It has maintained this success for over half a century 
(although there are now considerable efforts underway to develop improved anticoagulants [119]).  
While some drugs targeting NQO1 are nearing clinical use (for example, EO9 has shown considerable 
promise in phase I and II clinical trials for bladder cancer [120]), none of those based on the 
dicoumarol structure are at this stage.  However, given the success of combined computational and 
biochemical studies in identifying molecules which have improved affinity for NQO1 together with 
lower off target effects there remains considerable promise in this avenue of research.  If it is 
successful, dicoumarol will be the “parent” of at least two families of drugs targeted at very different 
groups of diseases. 
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Figure and Scheme Legends 
Scheme 1:  The tautomeric forms of dicoumarol 
Scheme 2:  The structure of warfarin and two computationally identified analogues 
Scheme 3:  The structures of common forms of vitamin K1 and vitamin K2 
Scheme 4:  Forms of vitamin K which occur during the γ-carboxylation cycle 
Scheme 5:  Inhibitors of NQO1 with structures related to dicoumarol 
 
Figure 1:  The structure of VKOR.  (a) The crystal structure of cyanobacterial VKOR with bound 
quinone (space filling model, dark grey).  The C-terminal thioredoxin-like domain is shown at the top 
of the figure and VKOR-like subunit at the bottom.  The VKOR-like subunit consists largely of four, 
membrane-spanning helices.  The figure was produced using PDB file 3KP9 [47] and PyMol 
(www.pymol.org).  The N- and C-termini are indicated.  (b) A homology model of human VKOR 
using the cyanobacterial VKOR as a template.  This protein lacks the thioredoxin-like domain.  The 
model was generated using Phyre2 in the intensive mode [121].  It aligns to the cyanobacterial 
structure with a root mean square deviation (rmsd) of 4.27 Å over 687 equivalent atoms.  The N- and 
C-termini are indicated.  (c) A structure-based sequence alignment (generated in PROMALS3D 
[122]) of cyanobacterial VKOR (3KP9) and human VKOR (VKOR) showing regions which are α-
helical (h) and in β-sheets (e). 
Figure 2:  The location of residues in human VKOR which are altered by mutations associated either 
with disease or with increased tolerance to warfarin.  The overall fold of the protein was predicted by 
homology modelling (see Fig. 1) and the residues affected are shown in stick form and dark grey.  
The N- and C-termini and the residues which are associated with resistance to warfarin are indicated.  
The right hand image represents the protein rotated by 90° around the x-axis compared to the left hand 
one.  Images were generated using PyMol. 
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Figure 3:  Docked structures of (a) dicoumarol and (b) warfarin with the VKOR homology model (see 
Fig. 1).  Docking was achieved using AutoDock Vina as implemented in Chimera [69, 70].  The 
proteins and ligands were prepared using the default settings DockPrep prior to docking.  In both (a) 
and (b) the left hand image shows the overall fold of the protein (generated using PyMol) with the 
bound ligand (dark grey).  The right hand images show the amino acid residues which are predicted to 
be close to the ligands.  These images were generated with Discovery Studio Visualiser 3.5 (Accelrys 
Software Inc., USA). 
Figure 4:  The structure of human NQO1 with dicoumarol bound.  The left hand image shows the 
overall, dimeric fold of the protein with the FAD cofactors and dicoumarol ligands bound at both 
active sites (top right and bottom left of the structure).  The two subunits of the dimer are coloured 
dark and light grey.  The N- and C-termini of both subunits are indicated.  The right hand image 
shows the dicoumarol ligand (top) and the FAD cofactor (bottom) only, demonstrating how they stack 
onto each other.  The figures were produced using PDB file 2F1O [90] and PyMol. 
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VKOR    1  MGSTWGSPGWVRLALCLTGLVLSLYALHVKAARARDRDYRALCDVGTAISCSRVFSSRWGRGFGLVEHVL   
3KP9    1  ----QRHSRLILAILAGLGSLLTAYLTYTKLTEQP----AAFCT-----GSDLVLSSRWAEFLGIPTAAV   
                 hhhhhhhhhhhhhhhhhhhhhhhhhhhhhh  hhhhh     eehhhhh    hhhh  hhhhh 
  
VKOR    71  GQDSILNQSNSIFGCIFYTLQLLLGCLR--TRWASVLMLLSSLVSLAGSVYLAWILFFVLYDFCIVCITT   
3KP9    58  GLLGFLGVL---------ALAVLPL--PLVKRWRWPALFGLVSAMTAFEMYMLYLMVAVLRQFCMYCTTA   
            hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh 
  
VKOR   139  YAINVSLMWLSFRKVQEPQG---KAKRH------------------------------------------   
3KP9   117  IILVAGLGLVTVLGHR-WLDGGKLAFSYILVAFLTLVTTIGVYANQVPPPSPLAVGLAAHLRQIGGTMYG   
            hhhhhhhhhhhhhhhh   h   hheeeeeeeeee                hhhhhhhhhhhh   eeee 
  
VKOR        ----------------------------------------------------------------------   
3KP9   186  AYWCPHCQDQKELFGAAFDQVPYVECSPNGPGTPQAQECTEAGITSYPTWIINGRTYTGVRSLEALAVAS   
                hhhhhhhhhhhhhh eeeeee          hhhhhh        eee  ee      hhhhhhhh 
  
VKOR        ----   
3KP9   256  GYPL   
(c) 
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Figure 2 
 
  
N 
C 
Ala-26 
Val-29 
Arg-33 
Arg-35 
Tyr-39 
Ala-41 
Val-45 
Val-54 
Trp-59 
Phe-63 
Glu-67 
His-68 
Leu-90 
Ser-113 
Ile-123 
Leu-128 
Tyr-139 
Asn-142 
26 
 
Figure 3 
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Figure 4 
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Scheme 1 
 
  
29 
 
Scheme 2 
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Scheme 3 
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Scheme 4 
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Scheme 5 
 
